Miscellaneous
Hear a 5-minute summary of a small study investigating whether the GLP-1 receptor agonist liraglutide affected diastolic function in people with type 2 diabetes, presented at ESC 2021 and later published Diabetes, Obesity and Metabolism. Listen for a quick overview of the key findings. Publication: Bojer AS, et al. Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2021 Oct;23(10):2374-2384. doi: 10.1111/dom.14480. Epub 2021 Jul 26. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.